HC Wainwright Has Negative Estimate for PVLA FY2027 Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Equities research analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a report released on Monday, December 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($3.65) per share for the year, down from their previous forecast of ($3.62). HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2028 earnings at ($2.42) EPS and FY2029 earnings at $0.25 EPS.

A number of other research firms have also commented on PVLA. Craig Hallum assumed coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective on the stock. Chardan Capital upped their target price on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a report on Monday. Canaccord Genuity Group lifted their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday. Finally, Truist Financial increased their target price on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $155.60.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $92.01 on Thursday. Palvella Therapeutics has a fifty-two week low of $11.17 and a fifty-two week high of $112.00. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -34.98 and a beta of -0.20. The stock has a fifty day moving average of $84.68 and a two-hundred day moving average of $56.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PVLA. Archer Investment Corp acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at $28,000. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics in the 3rd quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics during the second quarter valued at about $37,000. AlphaQuest LLC purchased a new stake in shares of Palvella Therapeutics during the third quarter worth about $164,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares in the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $86.23, for a total value of $370,961.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.